NeuroOne Medical Technologies (NMTC) 10-Q 14 Aug 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Jun. 30, 2023	Aug. 10, 2023
Document Information Line Items
Entity Registrant Name	NeuroOne Medical Technologies Corporation
Trading Symbol	NMTC
Document Type	10-Q
Current Fiscal Year End Date	--09-30
Entity Common Stock, Shares Outstanding		23,919,184
Amendment Flag	false
Entity Central Index Key	0001500198
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-40439
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-0863354
Entity Address, Address Line One	7599 Anagram Drive
Entity Address, City or Town	Eden Prairie
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55344
City Area Code	952
Local Phone Number	426-1383
Title of 12(b) Security	Common stock, $0.001 par value
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Current assets:
Cash and cash equivalents	$ 3,083,458	$ 8,160,329
Short-term investments		2,981,010
Accounts receivable		33,237
Inventory	1,516,527	704,538
Prepaids and other assets	278,786	296,649
Total current assets	4,878,771	12,175,763
Intangible assets, net	95,156	111,892
Right-of-use asset	197,324	181,355
Property and equipment, net	586,873	353,599
Total assets	5,758,124	12,822,609
Current liabilities:
Accounts payable	958,811	927,662
Accrued expenses and other liabilities	789,097	715,839
Deferred revenue		1,455,188
Total current liabilities	1,747,908	3,098,689
Operating lease liability, long term	88,918	119,556
Total liabilities	1,836,826	3,218,245
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized as of June 30, 2023 and September 30, 2022; no shares issued or outstanding as of June 30, 2023 and September 30, 2022.
Common stock, $0.001 par value; 100,000,000 shares authorized as of June 30, 2023 and September 30, 2022; 17,862,162 and 16,216,540 shares issued and outstanding as of June 30, 2023 and September 30, 2022, respectively.	17,862	16,217
Additional paid–in capital	63,454,618	60,414,959
Accumulated deficit	(59,551,182)	(50,826,812)
Total stockholders’ equity	3,921,298	9,604,364
Total liabilities and stockholders’ equity	$ 5,758,124	$ 12,822,609

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2023	Sep. 30, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	17,862,162	16,216,540
Common stock, shares outstanding	17,862,162	16,216,540

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Product revenue	$ 629,906	$ 32,049	$ 1,210,661	$ 102,381
Cost of product revenue	386,240	38,462	947,799	158,113
Product gross profit (loss)	243,666	(6,413)	262,862	(55,732)
Collaborations revenue			1,455,188	6,374
Operating expenses:
Selling, general and administrative	1,862,389	1,529,670	5,347,234	5,090,018
Research and development	1,891,512	1,225,351	5,161,322	3,491,193
Total operating expenses	3,753,901	2,755,021	10,508,556	8,581,211
Loss from operations	(3,510,235)	(2,761,434)	(8,790,506)	(8,630,569)
Other income, net	41,462	1,707	66,136	5,300
Loss before income taxes	(3,468,773)	(2,759,727)	(8,724,370)	(8,625,269)
Provision for income taxes
Net loss	$ (3,468,773)	$ (2,759,727)	$ (8,724,370)	$ (8,625,269)
Net loss per share:
Basic (in Dollars per share)	$ (0.2)	$ (0.17)	$ (0.52)	$ (0.54)
Number of shares used in per share calculations:
Basic (in Shares)	17,578,871	16,193,442	16,740,546	15,927,734

Condensed Statements of Opera_2

Condensed Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Net loss per share Diluted	$ (0.20)	$ (0.17)	$ (0.52)	$ (0.54)
Number of shares used in per share calculations Diluted	17,578,871	16,193,442	16,740,546	15,927,734

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Sep. 30, 2021	$ 12,010	$ 47,369,090	$ (40,827,199)	$ 6,553,901
Balance (in Shares) at Sep. 30, 2021	12,010,019
Issuance of common stock in connection with public offering	$ 4,172	13,346,410		13,350,582
Issuance of common stock in connection with public offering (in Shares)	4,172,057
Issuance cost in connection with public offering		(1,352,280)		(1,352,280)
Stock-based compensation		203,072		203,072
Issuance of common stock upon vesting of restricted stock units	$ 6	(6)
Issuance of common stock upon vesting of restricted stock units (in Shares)	5,646
Net loss			(2,807,475)	(2,807,475)
Balance at Dec. 31, 2021	$ 16,188	59,566,286	(43,634,674)	15,947,800
Balance (in Shares) at Dec. 31, 2021	16,187,722
Balance at Sep. 30, 2021	$ 12,010	47,369,090	(40,827,199)	6,553,901
Balance (in Shares) at Sep. 30, 2021	12,010,019
Net loss				(8,625,269)
Balance at Jun. 30, 2022	$ 16,195	60,054,543	(49,452,468)	10,618,270
Balance (in Shares) at Jun. 30, 2022	16,194,616
Balance at Dec. 31, 2021	$ 16,188	59,566,286	(43,634,674)	15,947,800
Balance (in Shares) at Dec. 31, 2021	16,187,722
Stock-based compensation		232,716		232,716
Issuance of common stock upon vesting of restricted stock units	$ 3	(3)
Issuance of common stock upon vesting of restricted stock units (in Shares)	3,447
Net loss			(3,058,067)	(3,058,067)
Balance at Mar. 31, 2022	$ 16,191	59,798,999	(46,692,741)	13,122,449
Balance (in Shares) at Mar. 31, 2022	16,191,169
Stock-based compensation		255,548		255,548
Issuance of common stock upon vesting of restricted stock units	$ 4	(4)
Issuance of common stock upon vesting of restricted stock units (in Shares)	3,447
Net loss			(2,759,727)	(2,759,727)
Balance at Jun. 30, 2022	$ 16,195	60,054,543	(49,452,468)	10,618,270
Balance (in Shares) at Jun. 30, 2022	16,194,616
Balance at Sep. 30, 2022	$ 16,217	60,414,959	(50,826,812)	9,604,364
Balance (in Shares) at Sep. 30, 2022	16,216,540
Stock-based compensation		300,181		300,181
Issuance of common stock upon vesting of restricted stock units	$ 22	(22)
Issuance of common stock upon vesting of restricted stock units (in Shares)	21,924
Net loss			(1,732,769)	(1,732,769)
Balance at Dec. 31, 2022	$ 16,239	60,715,118	(52,559,581)	8,171,776
Balance (in Shares) at Dec. 31, 2022	16,238,464
Balance at Sep. 30, 2022	$ 16,217	60,414,959	(50,826,812)	9,604,364
Balance (in Shares) at Sep. 30, 2022	16,216,540
Net loss				(8,724,370)
Balance at Jun. 30, 2023	$ 17,862	63,454,618	(59,551,182)	3,921,298
Balance (in Shares) at Jun. 30, 2023	17,862,162
Balance at Dec. 31, 2022	$ 16,239	60,715,118	(52,559,581)	8,171,776
Balance (in Shares) at Dec. 31, 2022	16,238,464
Issuance of common stock in connection with at-the-market offering program	$ 516	927,741		928,257
Issuance of common stock in connection with at-the-market offering program (in Shares)	516,484
Issuance costs in connection with the at-the-market offering program		(183,359)		(183,359)
Share repurchases for the payment of employee taxes	$ (67)	(98,583)		(98,650)
Share repurchases for the payment of employee taxes (in Shares)	(67,109)
Stock-based compensation		237,628		237,628
Issuance of common stock upon vesting of restricted stock units	$ 200	(200)
Issuance of common stock upon vesting of restricted stock units (in Shares)	199,899
Net loss			(3,522,828)	(3,522,828)
Balance at Mar. 31, 2023	$ 16,888	61,598,345	(56,082,409)	5,532,824
Balance (in Shares) at Mar. 31, 2023	16,887,738
Issuance of common stock in connection with at-the-market offering program	$ 923	1,623,476		1,624,399
Issuance of common stock in connection with at-the-market offering program (in Shares)	923,193
Issuance costs in connection with the at-the-market offering program		(51,366)		(51,366)
Share repurchases for the payment of employee taxes	$ (8)	(12,180)		(12,188)
Share repurchases for the payment of employee taxes (in Shares)	(8,385)
Stock-based compensation		296,402		296,402
Issuance of common stock upon vesting of restricted stock units	$ 59	(59)
Issuance of common stock upon vesting of restricted stock units (in Shares)	59,616
Net loss			(3,468,773)	(3,468,773)
Balance at Jun. 30, 2023	$ 17,862	$ 63,454,618	$ (59,551,182)	$ 3,921,298
Balance (in Shares) at Jun. 30, 2023	17,862,162

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating activities
Net loss	$ (8,724,370)	$ (8,625,269)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization and depreciation	136,757	85,198
Stock-based compensation	834,211	691,336
Amortization of discounts and premiums on short-term investments	(45,571)
Non-cash lease expense	81,567	80,020
Change in assets and liabilities:
Accounts receivable	33,237	48,336
Inventory	(811,989)	(355,998)
Prepaids and other assets	85,022	(145,462)
Accounts payable	(62,808)	(87,197)
Accrued expenses, deferred revenue, operating leases and other liabilities	(1,510,104)	(228,315)
Net cash used in operating activities	(9,984,048)	(8,537,351)
Investing activities
Purchases of short-term investments	(1,473,419)
Maturities of short-term investments	4,500,000
Purchase of property and equipment	(326,497)	(209,044)
Net cash provided by (used in) investing activities	2,700,084	(209,044)
Financing activities
Proceeds from issuance of common stock in connection with at-the-market offering program and public offering	2,552,656	13,350,582
Issuance costs related to at-the-market offering program and public offering	(234,725)	(1,327,300)
Share repurchases for the payment of employee taxes	(110,838)
Net cash provided by financing activities	2,207,093	12,023,282
Net (decrease) increase in cash and cash equivalents	(5,076,871)	3,276,887
Cash and cash equivalents at beginning of period	8,160,329	6,901,346
Cash and cash equivalents at end of period	3,083,458	10,178,233
Supplemental non-cash financing and investing transactions:
Reclass of deferred offering costs to additional paid-in capital in connection with public offering		24,980
Modification of right-of-use asset and associated lease liability	97,536
Unpaid deferred issuance costs (offset in prepaids and other assets)	67,159
Purchased property and equipment in accounts payable	$ 26,798

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Jun. 30, 2023
Description of Business and Basis of Presentation [Abstract]
Description of Business and Basis of Presentation	NOTE 1 – Description of Business and Basis of Presentation NeuroOne Medical Technologies Corporation (the “Company” or “NeuroOne”), a Delaware corporation, is an early-stage medical technology company developing comprehensive neuromodulation electroencephalogram (“cEEG”) and stereoelectrocencephalography (“sEEG”) recording, monitoring, ablation, drug delivery and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The Company received 510(k) clearance from the United States (“U.S.”) Food and Drug Administration (“FDA”) for its Evo cortical electrode technology in November 2019 and in October 2022, the Company received 510(k) from the FDA clearance for its Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. The Company is based in Eden Prairie, Minnesota. Global Economic Conditions Generally, worldwide economic conditions remain uncertain, particularly due to the conflict between Russia and Ukraine, disruptions in the banking system and financial markets, lingering effects of the COVID-19 pandemic and increased inflation. The general economic and capital market conditions both in the U.S. and worldwide, have been volatile in the past and at times have adversely affected the Company’s access to capital and increased the cost of capital. The capital and credit markets may not be available to support future capital raising activity on favorable terms or at all. If economic conditions continue to decline, the Company’s future cost of equity or debt capital and access to the capital markets could be adversely affected. The COVID-19 pandemic that began in late 2019 introduced significant volatility to the global economy, disrupted supply chains and had a widespread adverse effect on the financial markets. Additionally, the Company’s operating results could be materially impacted by changes in the overall macroeconomic environment and other economic factors. Changes in economic conditions, supply chain constraints, logistics challenges, labor shortages, the conflict in Ukraine, disruptions in the banking system and financial markets, and steps taken by governments and central banks, particularly in response to the COVID-19 pandemic as well as other stimulus and spending programs, have led to higher inflation, which has led to an increase in costs and has caused changes in fiscal and monetary policy, including increased interest rates. Basis of presentation The accompanying unaudited condensed financial statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The condensed financial statements may not include all disclosures required by U.S. GAAP; however, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended September 30, 2022 included in the Annual Report on Form 10-K. The condensed balance sheet at September 30, 2022 was derived from the audited financial statements of the Company. In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, have been made. The results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods.

Going Concern

Going Concern	9 Months Ended
	Jun. 30, 2023
Going Concern [Abstract]
Going Concern	NOTE 2 – Going Concern The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses since inception, negative cash flows from operations, and an accumulated deficit of $59.6 million as of June 30, 2023. To date, the Company’s revenues have not been sufficient to cover its full operating costs, and as such, has been dependent on funding operations through the issuance of debt and sale of equity securities. With the July 2023 Public Offering (see Note 13 - Subsequent Events), the Company has adequate liquidity to fund its operations through March 31, 2024. The raising of additional funds is not solely within the control of the Company. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this condition. If the Company is unable to raise additional funds, or the Company’s anticipated operating results are not achieved, management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the Company’s operations. The Company intends to fund ongoing activities by utilizing its current cash and cash equivalents on hand, from product and collaborations revenue and by raising additional capital through equity or debt financings. If management is unable to obtain the necessary capital, it may have a material adverse effect on the operations of the Company and the development of its technology, or the Company may have to cease operations altogether.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 3 – Summary of Significant Accounting Policies Management’s Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original contractual maturity on date of purchase of less than or equal to three months to be classified and presented as cash equivalents on the Balance Sheets. Cash equivalents are stated at cost, which approximates fair value. The Company’s cash and cash equivalents may include demand deposit accounts with large financial institutions, institutional money market funds, U.S. Treasury securities, and corporate notes and bonds. The Company monitors the creditworthiness of the financial institutions, institutional money market funds, and corporations in which the Company invests its surplus funds. The Company has experienced no credit losses from its cash and cash equivalent investments. Short-Term Investments The Company has invested its excess cash in U.S. Treasury securities and highly rated corporate securities in prior periods. The Company has held these investments to maturity. Securities with original maturity dates of more than three months were reported as held-to-maturity investments and were recorded at amortized cost, which approximated fair value due to the negligible risk of changes in value due to interest rates. All investments held as September 30, 2022 had contractual maturities of less than one year. The were no short-term investments outstanding as of June 30, 2023. The amortized cost and estimated fair values of the Company’s investments as of September 30, 2022 were as follows: September 30, 2022 Unrealized Unrealized Amortized Holding Holding Fair Short-term: U.S. treasury and corporate notes $ 2,981,010 $ — $ 2,870 $ 2,978,140 Total $ 2,981,010 $ — $ 2,870 $ 2,978,140 Revenue Recognition The Company entered into a development and distribution agreement which has current and future revenue recognition implications. See “Note 7 – Zimmer Development Agreement.” In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Account Standards Codification (“ASC”) Topic 606. (“ASC 606”). Performance obligations may include license rights, development services, and services associated with regulatory submission and approval processes. Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations are either completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Product Revenue Revenues from product sales are recognized when control of the promised goods or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. At the inception of each customer contract, performance obligations are identified and the total transaction price is allocated to the performance obligations. Cost of Product Revenue Cost of product revenue consists of the manufacturing and materials costs incurred by the Company’s third-party contract manufacturer in connection with the Company’s strip and grid cortical electrodes (the “Strip/Grid Products”), depth electrodes (“sEEG Products) and outside supplier materials costs in connection with the . In addition, cost of product revenue includes royalty fees incurred in connection with the Company’s license agreements. Collaborations Revenue As part of the accounting for collaboration arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation. Licenses of intellectual property Milestone payments Royalties Fair Value of Financial Instruments The Company’s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (“FASB”) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: ● Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date. ● Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. ● Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. As of June 30, 2023 and September 30, 2022, the fair values of cash, cash equivalents, short-term investments, accounts receivable, inventory, prepaids and other assets, accounts payable and accrued expenses and other liabilities approximated their carrying values because of the short-term nature of these assets or liabilities. There were no transfers between fair value hierarchy levels during the three or nine months ended June 30, 2023 and 2022. Intellectual Property The Company has entered into two licensing agreements with major research institutions, which allow for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology. Property and Equipment Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for equipment and furniture ranges from three to seven years and three years for software. Tangible assets acquired for research and development activities and that have alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and, when appropriate, changes are made prospectively. Software purchased for internal use consists primarily of amounts paid for perpetual licenses to third-party software providers and installation costs. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred. Impairment of Long-Lived Assets The Company evaluates its long-lived assets, which consist of licensed intellectual property, property and equipment and right-of-use assets for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Allowances for Doubtful Accounts The Company records a provision for doubtful accounts, when appropriate, based on historical experience and a detailed assessment of the collectability of its accounts receivable. In estimating the allowance for doubtful accounts, the Company considers, among other factors, the aging of the accounts receivable, its historical write-offs, the credit worthiness of each customer, and general economic conditions. Account balances are charged off against the allowance when the Company believes that it is probable that the receivable will not be recovered. Actual write-offs may be in excess of the Company’s estimated allowance. Inventories Inventories are stated at the lower of cost (using the first-in, first-out “FIFO” method) or net realizable value. The Company calculates inventory valuation adjustments for excess and obsolete inventory, when appropriate, based on current inventory levels, movement, expected useful lives, and estimated future demand of the products and spare parts. The Company’s inventory is currently comprised of Strip/Grid Products, sEEG and electrode cable assembly work-in-process and finished good product. The Strip/Grid Products and sEEG Products are produced by a third-party contract manufacturer and the Electrode Cable Assembly Products are obtained from outside suppliers. Research and Development Costs Research and development costs are charged to expense as incurred. Research and development expenses may include costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730, Research and Development Selling, General and Administrative Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include legal and litigation costs relating to corporate matters, intellectual property costs, professional fees for consultants assisting with regulatory, clinical, product development, financial matters, and sales and marketing in connection with the commercial sales of the Company’s products. Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the provisions of ASC 718, Compensation — Stock Compensation Income Taxes For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Net Loss Per Share For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s warrants, stock options, and restricted stock units while outstanding are considered common stock equivalents for this purpose. Diluted earnings or loss per share of common stock is computed utilizing the treasury method for the warrants, stock options and restricted stock units. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three and nine months ended June 30, 2023 and 2022. The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three and nine months ended June 30, 2023 and 2022: 2023 2022 Warrants 6,407,495 6,753,444 Stock options 1,708,906 1,245,582 Restricted stock units 431,049 443,670 Recent Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, “ Financial Instruments – Credit Losses” In August 2020, FASB issued ASU 2020-06 , Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jun. 30, 2023
Commitments and Contingencies [Abstarct]
Commitments and Contingencies	NOTE 4 - Commitments and Contingencies WARF License Agreement The Company has entered into an exclusive start-up company license agreement with the Wisconsin Alumni Research Foundation (“WARF”) for WARF’s neural probe array and thin film micro electrode technology (the “WARF License”). The WARF License grants to the Company an exclusive license to make, use and sell, in the United States only, products that employ certain licensed patents for a neural probe array or thin-film micro electrode array and method. The Company agreed to pay WARF a royalty equal to a single-digit percentage of our product sales pursuant to the WARF License, with a minimum annual royalty payment of $50,000 for 2020, $100,000 for 2021 and $150,000 for 2022 and each calendar year thereafter that the WARF License is in effect. If the Company or any of its sublicensees contest the validity of any licensed patent, the royalty rate will be doubled during the pendency of such contest and, if the contested patent is found to be valid and would be infringed by the Company if not for the WARF License, the royalty rate will be tripled for the remaining term of the WARF License. WARF may terminate the WARF License on 30 days’ written notice if we default on the payments of amounts due to WARF or fail to timely submit development reports, actively pursue our development plan or breach any other covenant in the WARF License and fail to remedy such default in 90 days or in the event of certain bankruptcy events involving us. The WARF License otherwise expires by its terms on the date that no valid claims on the patents licensed thereunder remain. The Company expects the latest expiration of a licensed patent to occur in 2030. During the three months ended June 30, 2023 and 2022, $37,500 in royalty fees were incurred related to the WARF License during each of these periods. During the nine months ended June 30, 2023 and 2022, $112,500 and $100,000 in royalty fees were incurred related to the WARF License, respectively. The royalty fees were reflected as a component of cost of product revenue. Mayo Agreement The Company has an exclusive license and development agreement with the Mayo Foundation for Medical Education and Research (“Mayo”) related to certain intellectual property and development services for thin film micro electrode technology (“Mayo Agreement”). If the Company is successful in obtaining regulatory approval, the Company is to pay royalties to Mayo based on a percentage of net sales of products of the licensed technology through the term of the Mayo Agreement, set to expire May 25, 2037. During the three months ended June 30, 2023 and 2022, $5,727 and $962 in royalty fees were incurred related to the Mayo Agreement, respectively. During the nine months ended June 30, 2023 and 2022, $6,417 and $2,798 in royalty fees were incurred related to the Mayo Agreement, respectively. The royalty fees were reflected as a component of cost of product revenue. Facility Leases Headquarters Lease On October 7, 2019, the Company entered into a non-cancellable lease agreement (the “Lease”) with certain landlords (together, the “Landlord”) pursuant to which the Company has agreed to lease office space located at 7599 Anagram Drive, Eden Prairie, Minnesota (the “Premises”). The Company took possession of the Premises on November 1, 2019, with the term of the Lease ending 65 months after such date, unless terminated earlier (the “Term”). The initial base rent for the Premises is $6,410 per month for the first 17 months, increasing to $7,076 per month by the end of the Term. In addition, as long as the Company is not in default under the Lease, the Company shall be entitled to an abatement of its base rent for the first 5 months. In addition, the Company will pay its pro rata share of the Landlord’s annual operating expenses associated with the premises, calculated as set forth in the Lease of which the Company is entitled to an abatement of these operating expense for the first 3 months. Los Gatos Lease On July 1, 2021, the Company entered into a non-cancellable facility lease (the “Los Gatos Lease”), pursuant to which the Company agreed to rent office space for its research and development operations located at 718 University Avenue, Suite #111, Los Gatos, California. The facility space under the Los Gatos Lease is approximately 1,162 square feet. The Company took possession of the office space on July 2, 2021. The initial monthly rent under the Los Gatos Lease was approximately $4,241. On November 4, 2022, the Los Gatos Lease was extended for an additional two years to December 31, 2024. The rent under the extended Los Gatos Lease ranges from $4,453 to $4,632 per month beginning on January 1, 2023. During the three and nine months ended June 30, 2023, rent expense associated with the facility leases amounted to $43,053 and $128,580, respectively. During the three and nine months ended June 30, 2022, rent expense associated with the facility leases amounted to $42,185 and $128,315, respectively Supplemental cash flow information related to the operating leases was as follows: For the 2023 2022 Cash paid for amounts included in the measurement of lease liability: Operating cash flows from operating leases $ 100,562 $ 97,799 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 97,536 $ — Supplemental balance sheet information related to the operating leases was as follows: As of As of Right-of-use assets $ 197,324 $ 181,355 Lease liabilities $ 214,482 $ 202,895 Weighted average remaining lease term (years) 1.7 2.4 Weighted average discount rate 7.8 % 6.9 % Maturity of the lease liabilities was as follows: Calendar Year As of 2023 $ 68,139 2024 139,969 2025 21,227 Total lease payments 229,335 Less imputed interest (14,853 ) Total 214,482 Short-term portion in accrued expenses and other liabilities (125,564 ) Long-term portion $ 88,918 Other In the ordinary course of business, from time to time, the Company may be subject to a broad range of claims and legal proceedings that relate to contractual allegations, patent infringement and other claims. The Company establishes accruals when applicable for matters and commitments which it believes losses are probable and can be reasonably estimated. To date, no loss contingency for such matters and potential commitments have been recorded. Although it is not possible to predict with certainty the outcome of these matters or potential commitments, the Company is of the opinion that the ultimate resolution of these matters and potential commitments will not have a material adverse effect on its results of operations or financial position.

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	9 Months Ended
	Jun. 30, 2023
Supplemental Balance Sheet Information [Abstract]
Supplemental Balance Sheet Information	NOTE 5 – Supplemental Balance Sheet Information Prepaid and other assets consisted of the following: As of June 30, As of September 30, Prepaid expenses $ 211,627 $ 296,649 Deferred offering costs 67,159 — Total $ 278,786 $ 296,649 As of June 30, 2023, the Company incurred deferred issuance costs in the amount of $67,159 related to a pending financing. See Note 13 – Subsequent Events. Inventory Inventory consisted of the following: As of June 30, As of September 30, Work-in-process $ 1,323,508 $ 630,570 Finished goods 193,019 73,968 Total $ 1,516,527 $ 704,538 Intangibles Intangible assets rollforward is as follows: Useful Life Net Intangibles, September 30, 2022 12-13 years $ 111,892 Less: amortization (16,736 ) Net Intangibles, June 30, 2023 $ 95,156 Amortization expense was $5,578 and $16,736 for the three and nine months ended June 30, 2023, respectively, and $5,578 and $16,736 for the three and nine months ended June 30, 2022, respectively. Property and Equipment, Net Property and equipment held for use by category are presented in the following table: As of As of Equipment and furniture $ 891,356 $ 538,061 Software — 1,895 Total property and equipment 891,356 539,956 Less accumulated depreciation (304,483 ) (186,357 ) Property and equipment, net $ 586,873 $ 353,599 Depreciation expense was $51,380 and $120,021 for the three months and nine months ended June 30, 2023, respectively, and $25,928 and $68,462 for the three months and nine months ended June 30, 2022, respectively. Software assets were fully depreciated as of September 30, 2022 and were written-off during the third quarter of 2023.

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	9 Months Ended
	Jun. 30, 2023
Accrued Expenses and Other Liabilities [Abstract]
Accrued Expenses and Other Liabilities	NOTE 6 - Accrued Expenses and Other Liabilities Accrued expenses and other liabilities consisted of the following: As of As of Accrued payroll $ 582,806 $ 521,368 Operating lease liability, short term 125,564 83,339 Royalty payments 80,727 111,132 Total $ 789,097 $ 715,839

Zimmer Development Agreement

Zimmer Development Agreement	9 Months Ended
	Jun. 30, 2023
Zimmer Development Agreement [Abstract]
Zimmer Development Agreement	NOTE 7 – Zimmer Development Agreement On July 20, 2020, the Company entered into an exclusive development and distribution agreement (as amended from time to time, the “Zimmer Development Agreement”) with Zimmer, Inc. (“Zimmer”), pursuant to which the Company granted Zimmer exclusive global rights to distribute the Strip/Grid Products and electrode cable assembly products (the “Electrode Cable Assembly Products”). Additionally, the Company granted Zimmer the exclusive right and license to distribute certain depth electrodes developed by the Company (“sEEG Products”, and together with the Strip/Grid Products and Electrode Cable Assembly Products, the “Products”). The parties have agreed to collaborate with respect to development activities under the Zimmer Development Agreement through a joint development committee composed of an equal number of representatives of Zimmer and the Company. Under the terms of the Zimmer Development Agreement, the Company is responsible for all costs and expenses related to developing the Products, and Zimmer is responsible for all costs and expenses related to the commercialization of the Products. In addition to the Zimmer Development Agreement, Zimmer and the Company have entered into a Manufacturing and Supply Agreement (the “MS Agreement”) and a supplier quality agreement (the “Quality Agreement”) with respect to the manufacturing and supply of the Products. Except as otherwise provided in the Zimmer Development Agreement, the Company is responsible for performing all development activities, including non-clinical and clinical studies directed at obtaining regulatory approval of each Product. Zimmer has agreed to use commercially reasonable efforts to promote, market and sell each Product following the “Product Availability Date” (as defined in the Zimmer Development Agreement) for such Product. Pursuant to the Zimmer Development Agreement, Zimmer made an upfront initial exclusivity fee payment of $2.0 million (the “Initial Exclusivity Fee”) to the Company in fiscal year 2020. On August 2, 2022, the Company entered into a Third Amendment to the Zimmer Development Agreement (the “Third Amendment”) with Zimmer. Pursuant to the terms and conditions of the Third Amendment, Zimmer made a $3.5 million payment to the Company. ● $1.5 million for the sEEG Exclusivity Maintenance Fee; and ● $2.0 million for satisfaction of each of the milestone events related to the design of sEEG products set forth in the Zimmer Development Agreement even though the satisfaction was after the deadlines originally identified. In addition, in connection with the Third Amendment, the Company issued Zimmer a warrant to purchase common stock (the “2022 Zimmer Warrant”). The 2022 Zimmer Warrant is exercisable for up to an aggregate of 350,000 shares of the Company’s common stock. The 2022 Zimmer Warrant has an exercise price of $3.00 per share, will be exercisable commencing six months from the issuance date, and will expire on August 2, 2027. The fair value of the 2022 Zimmer Warrant of $0.1 million was based on the Black-Scholes pricing model. Input assumptions used were as follows: a risk-free interest rate of 2.9%; expected volatility of 53.5%; expected life of 5 years; expected dividend yield of 0%; and the underlying fair market of the common stock. The 2022 Zimmer Warrant was classified in stockholders’ equity as the number of shares were fixed and determinable, no cash settlement was required and no other provisions precluded equity treatment. The Zimmer Development Agreement will expire on the tenth anniversary of the date of the first commercial sale of the last Products to achieve a first commercial sale, unless terminated earlier pursuant to its terms. Either party may terminate the Zimmer Development Agreement (x) with written notice for the other party’s material breach following a cure period or (y) if the other party becomes subject to certain insolvency proceedings. In addition, Zimmer may terminate the Zimmer Development Agreement for any reason with 90 days’ written notice, and the Company may terminate the Zimmer Development Agreement if Zimmer acquires or directly or indirectly owns a controlling interest in certain competitors of the Company. The license rights granted to Zimmer under the Strip/Grid Distribution License and sEEG Distribution License shall be exclusive from the effective date of the Third Amendment until the end of the term. The Zimmer Development Agreement and Third Amendment were accounted for under the provisions of ASC 606. In accordance with the provisions under ASC 606, the Company identified five performance obligations under the Zimmer Development Agreement and Third Amendment: (1) the Company’s obligation to grant Zimmer access to its intellectual property; (2) completion of sEEG Product development; (3) completion of Strip/Grid Product development; (4) the provision of sEEG exclusivity maintenance; and (5) completion of sEEG design modifications as requested by Zimmer. All performance obligations under the Zimmer Development Agreement and Third Amendment were met as of December 31, 2022. The aggregate transaction price associated with the Zimmer Development Agreement and Third Amendment was $5.4 million comprising the Initial Exclusivity Fee of $2.0 million and the $3.5 million payment under the Third Amendment, less the fair value of the 2022 Zimmer Warrant of $0.1 million. The transaction price was allocated between performance obligations based on their relative standalone selling prices. The Company used a market based valuation approach and an expected cost plus margin approach with regard to estimating the standalone selling price for the performance obligations. In October 2022, the Company received 510(k) clearance from the FDA for its Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. Accordingly, the Company recognized revenue in the amount of zero and $1,455,188 during the three and nine months ended June 30, 2023, respectively, related to the completion of the sEEG exclusivity maintenance milestone. During the three and nine months ended June 30, 2022, the Company recognized revenue in the amount of zero and $6,374 related to sEEG Product development, respectively. A reconciliation of the closing balance of deferred revenue related to the Zimmer Development Agreement and Third Amendment is as follows during the nine months ended as of June 30, 2023 and 2022: 2023 2022 Deferred Revenue Balance as of beginning of period $ 1,455,188 $ 8,622 Revenue recognized (1,455,188 ) (6,374 ) Balance as of end of period $ — $ 2,248 Product Revenue Product revenue related to its Strip/Grid Products, sEEG Products and Electrode Cable Assembly Products. Product revenue recognized during the three and nine months ended June 30, 2023 was $629,906 and $1,210,661, respectively. Product revenue recognized during the three and nine months ended June 30, 2022 was $32,049 and $102,381, respectively. Advertising Expense Advertising expense is charged to selling, general and administrative expenses during the period that it is incurred. Total advertising expense amounted to $49,492 and $156,131 for the three and nine months ended June 30, 2023, respectively. Total advertising expense amounted to $43,479 and $218,011 for the three and nine months ended June 30, 2022, respectively.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Jun. 30, 2023
Stock-Based Compensation [Abstract]
Stock-Based Compensation	NOTE 8 – Stock-Based Compensation During the three and nine months ended June 30, 2023 and 2022, stock-based compensation expense related to stock-based awards was included in selling, general and administrative and research and development costs as follows in the accompanying condensed statements of operations. Three Months Ended Nine Months Ended June 30, June 30, 2023 2022 2023 2022 Selling, general and administrative $ 237,007 $ 211,472 $ 691,939 $ 569,347 Research and development 59,395 44,076 142,272 121,989 Total stock-based compensation expense $ 296,402 $ 255,548 $ 834,211 $ 691,336 Stock Options During the three months ended June 30, 2023 and 2022, under the 2017 Equity Incentive Plan (the “2017 Plan”), the Company granted 339,000 and 88,890 stock options, respectively, to its board of directors, officers and employees. During the nine months ended June 30, 2023 and 2022, the Company granted 469,512 and 150,690, respectively, to its board of directors, officers, employees and consultants. Vesting generally occurs over an immediate to four-year period based on a time of service condition although vesting acceleration is provided under one grant in the event that a certain milestone is met. The grant date fair value of the grants issued during the three months ended June 30, 2023 and 2022 was $0.92 and $0.57 per share, respectively. The grant date fair value of the grants issued during the nine months ended June 30, 2023 and 2022 was $0.88 and $0.76 per share, respectively. The total expense for the three months ended June 30, 2023 and 2022 related to stock options was $158,528 and $137,109, respectively. The total expense for the nine months ended June 30, 2023 and 2022 related to stock options was $482,276 and $444,891, respectively. The total number of stock options outstanding as of June 30, 2023 and September 30, 2022 was 1,708,906 and 1,239,915, respectively. The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the three and nine months ended June 30, 2023 and 2022: Three Months Ended Nine Months Ended June 30, June 30, 2023 2022 2023 2022 Expected stock price volatility 58.1 % 53.5 % 57.4 % 53.5 % Expected life of options (years) 6.1 5.3 5.8 5.6 Expected dividend yield 0 % 0 % 0 % 0 % Risk free interest rate 3.6 % 2.8 % 3.7 % 2.3 % During the three months ended June 30, 2023 and 2022, 69,947 and 64,841 stock options vested, respectively, and 521 and 5,167 stock options were forfeited during these periods, respectively. During the nine months ended June 30, 2023 and 2022, 282,172 and 265,901 stock options vested, respectively, and 521 and 27,668 stock options were forfeited during these periods, respectively. During the three and nine months ended June 30, 2023 and 2022, no options were exercised. Restricted Stock Units During the three and nine months ended June 30, 2023, the Company granted an aggregate of 249,000 and 310,728 restricted stock units (“RSUs”) to its board of directors under the 2017 Plan, respectively. The weighted average grant date fair value of the RSUs granted during the three and nine months ended June 30, 2023 was $1.59 and $1.60 per unit, respectively. The RSUs vest over a one to three year period with some of the RSUs vesting ratably on a monthly and others vesting at 50 percent on the first anniversary of the grant date with the remaining RSUs vesting in equal monthly installments on the last day of each month over 24 months, subject to the recipient’s continued service on such dates. During the three and nine months ended June 30, 2022, the Company granted an aggregate of 87,720 and 443,670 RSUs to certain directors, officers and employees under the 2017 Plan. The weighted average grant date fair value of the RSUs granted during the three and nine months ended June 30, 2022 was $1.14 and $1.91 per unit, respectively. The RSUs vest over a one to three year period with some of the RSUs vesting ratably on a monthly and others vesting at 50 percent on the first anniversary of the grant date with the remaining RSUs vesting in equal monthly installments on the last day of each month over 24 months, subject to the recipient’s continued service on such dates. During the three months ended June 30, 2023 and 2022, 52,299 and 9,606 RSUs vested, respectively, and no RSUs were forfeited during these periods. During the nine months ended June 30, 2023 and 2022, 294,109 and 18,694 RSUs vested, respectively, and no RSUs were forfeited during these periods. The total expense for the three months ended June 30, 2023 and 2022 related to these RSUs was $137,874 and $118,439, respectively. The total expense for the nine months ended June 30, 2023 and 2022 related to these RSUs was $351,935 and $246,445, respectively. Inducement Plan On October 4, 2021, the Company adopted the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the “Inducement Plan”), pursuant to which the Company reserved 420,350 shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The Inducement Plan was approved by the Company’s Board of Directors without stockholder approval in accordance with such rule. 2017 Plan Evergreen Provision Under the 2017 Plan, the shares reserved automatically increase on January 1st of each year, for a period of not more than ten years from the date the 2017 Plan is approved by the stockholders of the Company, commencing on January 1, 2019 and ending on (and including) January 1, 2027, to an amount equal to 13% of the fully-diluted shares outstanding as of December 31st of the preceding calendar year. Notwithstanding the foregoing, the Company’s Board of Directors may act prior to January 1st of a given year to provide that there will be no January 1st increase in the share reserve for such year or that the increase in the share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. “Fully Diluted Shares” as of a date means an amount equal to the number of shares of common stock (i) outstanding and (ii) issuable upon exercise, conversion or settlement of outstanding awards under the 2017 Plan and any other outstanding options, warrants or other securities of the Company that are (directly or indirectly) convertible or exchangeable into or exercisable for shares of common stock, in each case as of the close of business of the Company on December 31 of the preceding calendar year. Effective January 1, 2023, 129,479 shares were added to the 2017 Plan as a result of the evergreen provision. General As of June 30, 2023, 1,129,125 shares were available in the aggregate for future issuance under the 2017 Plan and Inducement Plan. No shares were available for future issuance under the 2016 Equity Incentive Plan. Unrecognized stock-based compensation was $1,745,365 as of June 30, 2023. The unrecognized share-based expense is expected to be recognized over a weighted average period of 2.0 years.

Concentrations

Concentrations	9 Months Ended
	Jun. 30, 2023
Concentrations [Abstract]
Concentrations	NOTE 9 – Concentrations Revenue One customer accounts for all of the Company’s product and collaborations revenue. Supplier concentration One contract manufacturer produces all of the Company’s Strip/Grid Products and sEEG Products.

Income Taxes

Income Taxes	9 Months Ended
	Jun. 30, 2023
Income Taxes [Abstract]
Income Taxes	NOTE 10 – Income Taxes The effective tax rate for the three and nine months ended June 30, 2023 and 2022 was zero percent. As a result of the analysis of all available evidence as of June 30, 2023 and September 30, 2022, the Company recorded a full valuation allowance on its net deferred tax assets. Consequently, the Company reported no

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Jun. 30, 2023
Stockholders' Equity [Abstract]
Stockholders’ Equity	NOTE 11 – Stockholders’ Equity At-The-Market Offering On December 21, 2022, the Company entered into a Capital on Demand TM Public Offering On October 13, 2021, the Company, entered into an Underwriting Agreement (the “CH Underwriting Agreement”) with Craig-Hallum Capital Group LLC, as underwriter (“Craig-Hallum”), relating to the issuance and sale of 3,750,000 shares of the Company’s common stock at a price to the public of $3.20 per share. In addition, under the terms of the CH Underwriting Agreement, the Company granted Craig-Hallum an option, exercisable for 30 days, to purchase up to an additional 562,500 shares of common stock on the same terms. The base offering closed on October 15, 2021, and the sale of 422,057 shares of common stock subject to Craig-Hallum’s overallotment option closed on November 15, 2021. The gross proceeds to the Company from this offering were approximately $13.4 million prior to deducting underwriting discounts and other offering expenses payable by the Company in the amount of approximately $1.4 million in the aggregate. Warrant Activity and Summary There were no warrant exercises during the three and nine months ended June 30, 2023 and 425,370 and 695,848 warrants expired during the three and nine months ended June 30, 2023, respectively. The following table summarizes information about warrants outstanding at June 30, 2023: Exercise Price Number Outstanding Weighted Average Number Exercisable at $ 3.00 350,000 4.09 350,000 $ 5.25 4,166,682 2.55 4,166,682 $ 5.61 220,855 5.01 220,855 $ 6.00 45,171 1.01 45,171 $ 7.50 279,727 0.67 279,727 $ 8.25 62,906 1.01 62,906 $ 9.00 1,282,154 0.43 1,282,154 Total 6,407,495 6,407,495

Deferred Contribution Plan

Deferred Contribution Plan	9 Months Ended
	Jun. 30, 2023
Deferred Contribution Plan [Abstract]
Deferred Contribution Plan	NOTE 12 – Deferred Contribution Plan The Company has a 401(k) defined contribution plan (the “401K Plan”) for all employees aged 21 and over. Employees can defer up to 100% of their compensation through payroll withholdings into the 401K Plan subject to federal law limits. The Company may match 100% of deferrals up to 3% of one’s contributions. The Company’s matching contributions to employee deferrals are discretionary. The Company may also make discretionary profit sharing contributions under the 401K Plan in the future, but it has not done so through June 30, 2023. Employee contributions and any employer matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are 100% vested upon contribution. Discretionary employer matches to employee deferrals vest over a nine year period beginning on the second anniversary of an employee’s date of hire. Discretionary profit sharing contributions vest over a five year period beginning on the first anniversary of an employee’s date of hire. The amount of matching contributions to the 401K Plan to satisfy certain non-discrimination tests was zero and $30,697 during the three and nine months ending June 30, 2023 and 2022, respectively.

Subsequent Events

Subsequent Events	9 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	NOTE 13 – Subsequent Events ATM As of June 30, 2023, 1,439,677 shares of common stock were issued for gross proceeds of $2,552,656 under the ATM, and issuance costs in the amount of $234,725 have been incurred in connection with the ATM. On July 24, 2023, we decreased the amount of common stock that can be sold pursuant to the Sales Agreement, such that we are offering up to an aggregate of $2,560,000 of our common stock for sale under the Sales Agreement, including the shares of common stock previously sold. July 2023 Public Offering On July 24, 2023, the Company entered into an Underwriting Agreement (the “Benchmark Underwriting Agreement”) with The Benchmark Company, LLC, as underwriter (“Benchmark”), relating to the issuance and sale of 5,250,000 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $1.00 per share. In addition, under the terms of the Benchmark Underwriting Agreement, the Company granted Benchmark an option, exercisable for 30 days, to purchase up to an additional 787,500 shares of common stock on the same terms (“the Overallotment Option”). The offering closed on July 27, 2023, and the Company completed the sale and issuance of an aggregate of 6,037,500 shares of its common stock, including the exercise in full of the Overallotment Option. The net proceeds to the Company from this offering were approximately $5,214,875 after deducting underwriting discounts and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering to: (i) support the commercial launch of the EVO sEEG electrode with Zimmer Biomet, (ii) support the FDA submission for the OneRF ablation system and (iii) complete the design of a novel drug delivery electrode, among other general corporate purposes.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Management’s Use of Estimates	Management’s Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original contractual maturity on date of purchase of less than or equal to three months to be classified and presented as cash equivalents on the Balance Sheets. Cash equivalents are stated at cost, which approximates fair value. The Company’s cash and cash equivalents may include demand deposit accounts with large financial institutions, institutional money market funds, U.S. Treasury securities, and corporate notes and bonds. The Company monitors the creditworthiness of the financial institutions, institutional money market funds, and corporations in which the Company invests its surplus funds. The Company has experienced no credit losses from its cash and cash equivalent investments.
Short-Term Investments	Short-Term Investments The Company has invested its excess cash in U.S. Treasury securities and highly rated corporate securities in prior periods. The Company has held these investments to maturity. Securities with original maturity dates of more than three months were reported as held-to-maturity investments and were recorded at amortized cost, which approximated fair value due to the negligible risk of changes in value due to interest rates. All investments held as September 30, 2022 had contractual maturities of less than one year. The were no short-term investments outstanding as of June 30, 2023. The amortized cost and estimated fair values of the Company’s investments as of September 30, 2022 were as follows: September 30, 2022 Unrealized Unrealized Amortized Holding Holding Fair Short-term: U.S. treasury and corporate notes $ 2,981,010 $ — $ 2,870 $ 2,978,140 Total $ 2,981,010 $ — $ 2,870 $ 2,978,140
Revenue Recognition	Revenue Recognition The Company entered into a development and distribution agreement which has current and future revenue recognition implications. See “Note 7 – Zimmer Development Agreement.” In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Account Standards Codification (“ASC”) Topic 606. (“ASC 606”). Performance obligations may include license rights, development services, and services associated with regulatory submission and approval processes. Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations are either completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Product Revenue Revenues from product sales are recognized when control of the promised goods or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. At the inception of each customer contract, performance obligations are identified and the total transaction price is allocated to the performance obligations. Cost of Product Revenue Cost of product revenue consists of the manufacturing and materials costs incurred by the Company’s third-party contract manufacturer in connection with the Company’s strip and grid cortical electrodes (the “Strip/Grid Products”), depth electrodes (“sEEG Products) and outside supplier materials costs in connection with the . In addition, cost of product revenue includes royalty fees incurred in connection with the Company’s license agreements. Collaborations Revenue As part of the accounting for collaboration arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation. Licenses of intellectual property Milestone payments Royalties
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (“FASB”) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: ● Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date. ● Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. ● Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. As of June 30, 2023 and September 30, 2022, the fair values of cash, cash equivalents, short-term investments, accounts receivable, inventory, prepaids and other assets, accounts payable and accrued expenses and other liabilities approximated their carrying values because of the short-term nature of these assets or liabilities. There were no transfers between fair value hierarchy levels during the three or nine months ended June 30, 2023 and 2022.
Intellectual Property	Intellectual Property The Company has entered into two licensing agreements with major research institutions, which allow for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.
Property and Equipment	Property and Equipment Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for equipment and furniture ranges from three to seven years and three years for software. Tangible assets acquired for research and development activities and that have alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and, when appropriate, changes are made prospectively. Software purchased for internal use consists primarily of amounts paid for perpetual licenses to third-party software providers and installation costs. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates its long-lived assets, which consist of licensed intellectual property, property and equipment and right-of-use assets for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.
Allowances for Doubtful Accounts	Allowances for Doubtful Accounts The Company records a provision for doubtful accounts, when appropriate, based on historical experience and a detailed assessment of the collectability of its accounts receivable. In estimating the allowance for doubtful accounts, the Company considers, among other factors, the aging of the accounts receivable, its historical write-offs, the credit worthiness of each customer, and general economic conditions. Account balances are charged off against the allowance when the Company believes that it is probable that the receivable will not be recovered. Actual write-offs may be in excess of the Company’s estimated allowance.
Inventories	Inventories Inventories are stated at the lower of cost (using the first-in, first-out “FIFO” method) or net realizable value. The Company calculates inventory valuation adjustments for excess and obsolete inventory, when appropriate, based on current inventory levels, movement, expected useful lives, and estimated future demand of the products and spare parts. The Company’s inventory is currently comprised of Strip/Grid Products, sEEG and electrode cable assembly work-in-process and finished good product. The Strip/Grid Products and sEEG Products are produced by a third-party contract manufacturer and the Electrode Cable Assembly Products are obtained from outside suppliers.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred. Research and development expenses may include costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730, Research and Development
Selling, General and Administrative	Selling, General and Administrative Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include legal and litigation costs relating to corporate matters, intellectual property costs, professional fees for consultants assisting with regulatory, clinical, product development, financial matters, and sales and marketing in connection with the commercial sales of the Company’s products.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the provisions of ASC 718, Compensation — Stock Compensation
Income Taxes	Income Taxes For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.
Net Loss Per Share	Net Loss Per Share For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s warrants, stock options, and restricted stock units while outstanding are considered common stock equivalents for this purpose. Diluted earnings or loss per share of common stock is computed utilizing the treasury method for the warrants, stock options and restricted stock units. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three and nine months ended June 30, 2023 and 2022. The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three and nine months ended June 30, 2023 and 2022: 2023 2022 Warrants 6,407,495 6,753,444 Stock options 1,708,906 1,245,582 Restricted stock units 431,049 443,670
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, “ Financial Instruments – Credit Losses” In August 2020, FASB issued ASU 2020-06 , Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Schedule of Amortized Cost and Estimated Fair Values of the Company’s Investments	The amortized cost and estimated fair values of the Company’s investments as of September 30, 2022 were as follows: September 30, 2022 Unrealized Unrealized Amortized Holding Holding Fair Short-term: U.S. treasury and corporate notes $ 2,981,010 $ — $ 2,870 $ 2,978,140 Total $ 2,981,010 $ — $ 2,870 $ 2,978,140
Schedule of Computation of Diluted Net Loss Per Share	The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three and nine months ended June 30, 2023 and 2022: 2023 2022 Warrants 6,407,495 6,753,444 Stock options 1,708,906 1,245,582 Restricted stock units 431,049 443,670

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Jun. 30, 2023
Commitments and Contingencies [Abstarct]
Schedule of Supplemental Cash Flow Information Related to the Operating Lease	Supplemental cash flow information related to the operating leases was as follows: For the 2023 2022 Cash paid for amounts included in the measurement of lease liability: Operating cash flows from operating leases $ 100,562 $ 97,799 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 97,536 $ —
Schedule of Supplemental Balance Sheet Information Related to the Operating Lease	Supplemental balance sheet information related to the operating leases was as follows: As of As of Right-of-use assets $ 197,324 $ 181,355 Lease liabilities $ 214,482 $ 202,895 Weighted average remaining lease term (years) 1.7 2.4 Weighted average discount rate 7.8 % 6.9 %
Schedule of Maturity of the Lease Liabilities	Maturity of the lease liabilities was as follows: Calendar Year As of 2023 $ 68,139 2024 139,969 2025 21,227 Total lease payments 229,335 Less imputed interest (14,853 ) Total 214,482 Short-term portion in accrued expenses and other liabilities (125,564 ) Long-term portion $ 88,918

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	9 Months Ended
	Jun. 30, 2023
Supplemental Balance Sheet Information [Abstract]
Schedule of Prepaid and Other Assets	Prepaid and other assets consisted of the following: As of June 30, As of September 30, Prepaid expenses $ 211,627 $ 296,649 Deferred offering costs 67,159 — Total $ 278,786 $ 296,649
Schedule of Inventory Consisted	Inventory consisted of the following: As of June 30, As of September 30, Work-in-process $ 1,323,508 $ 630,570 Finished goods 193,019 73,968 Total $ 1,516,527 $ 704,538
Schedule of Intangible Assets	Intangible assets rollforward is as follows: Useful Life Net Intangibles, September 30, 2022 12-13 years $ 111,892 Less: amortization (16,736 ) Net Intangibles, June 30, 2023 $ 95,156
Schedule of Property and Equipment	Property and equipment held for use by category are presented in the following table: As of As of Equipment and furniture $ 891,356 $ 538,061 Software — 1,895 Total property and equipment 891,356 539,956 Less accumulated depreciation (304,483 ) (186,357 ) Property and equipment, net $ 586,873 $ 353,599

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	9 Months Ended
	Jun. 30, 2023
Accrued Expenses and Other Liabilities [Abstract]
Schedule of Accrued Expenses	Accrued expenses and other liabilities consisted of the following: As of As of Accrued payroll $ 582,806 $ 521,368 Operating lease liability, short term 125,564 83,339 Royalty payments 80,727 111,132 Total $ 789,097 $ 715,839

Zimmer Development Agreement (T

Zimmer Development Agreement (Tables)	9 Months Ended
	Jun. 30, 2023
Zimmer Development Agreement [Abstract]
Schedule of Deferred Revenue	A reconciliation of the closing balance of deferred revenue related to the Zimmer Development Agreement and Third Amendment is as follows during the nine months ended as of June 30, 2023 and 2022: 2023 2022 Deferred Revenue Balance as of beginning of period $ 1,455,188 $ 8,622 Revenue recognized (1,455,188 ) (6,374 ) Balance as of end of period $ — $ 2,248

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Jun. 30, 2023
Stock-Based Compensation [Abstract]
Schedule of Stock-Based Compensation Expense	During the three and nine months ended June 30, 2023 and 2022, stock-based compensation expense related to stock-based awards was included in selling, general and administrative and research and development costs as follows in the accompanying condensed statements of operations. Three Months Ended Nine Months Ended June 30, June 30, 2023 2022 2023 2022 Selling, general and administrative $ 237,007 $ 211,472 $ 691,939 $ 569,347 Research and development 59,395 44,076 142,272 121,989 Total stock-based compensation expense $ 296,402 $ 255,548 $ 834,211 $ 691,336
Schedule of Weighted-Average Assumptions Used in the Black-Scholes Option-Pricing Model	The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the three and nine months ended June 30, 2023 and 2022: Three Months Ended Nine Months Ended June 30, June 30, 2023 2022 2023 2022 Expected stock price volatility 58.1 % 53.5 % 57.4 % 53.5 % Expected life of options (years) 6.1 5.3 5.8 5.6 Expected dividend yield 0 % 0 % 0 % 0 % Risk free interest rate 3.6 % 2.8 % 3.7 % 2.3 %

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Jun. 30, 2023
Stockholders' Equity [Abstract]
Schedule of Summarizes Information About Warrants Outstanding	The following table summarizes information about warrants outstanding at June 30, 2023: Exercise Price Number Outstanding Weighted Average Number Exercisable at $ 3.00 350,000 4.09 350,000 $ 5.25 4,166,682 2.55 4,166,682 $ 5.61 220,855 5.01 220,855 $ 6.00 45,171 1.01 45,171 $ 7.50 279,727 0.67 279,727 $ 8.25 62,906 1.01 62,906 $ 9.00 1,282,154 0.43 1,282,154 Total 6,407,495 6,407,495

Going Concern (Details)

Going Concern (Details) $ in Millions	Jun. 30, 2023 USD ($)
Going Concern [Abstract]
Accumulated deficit	$ 59.6

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - Schedule of Amortized Cost and Estimated Fair Values of the Company’s Investments	Sep. 30, 2022 USD ($)
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	$ 2,981,010
Unrealized Holding Gains
Unrealized Holding Losses	2,870
Fair Value	2,978,140
U.S. treasury and corporate notes [Member]
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	2,981,010
Unrealized Holding Gains
Unrealized Holding Losses	2,870
Fair Value	$ 2,978,140

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of Computation of Diluted Net Loss Per Share - shares	3 Months Ended	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Schedule of Computation of Diluted Net Loss Per Share [Abstract]
Warrants	6,407,495	6,753,444
Stock options	1,708,906	1,245,582
Restricted stock units	431,049	443,670

Commitments and Contingencies_2

Commitments and Contingencies (Details)					3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 01, 2023 USD ($)	Nov. 04, 2022	Jul. 01, 2021 USD ($) m²	Oct. 07, 2019 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)
Commitments and Contingencies (Details) [Line Items]
Royalty payments - 2020											$ 50,000
Royalty payments - 2021										$ 100,000
Royalty payments - 2022									$ 150,000
Rent paid				$ 6,410
Lease space (in Square Meters) | m²			1,162
Lease rental expense			$ 4,241
Additional extended term		2 years
Lease extended period		Dec. 31, 2024
Rent expense					$ 43,053	$ 42,185	$ 128,580		$ 128,315
Minimum [Member]
Commitments and Contingencies (Details) [Line Items]
Lease rental expense	$ 4,453
Maximum [Member]
Commitments and Contingencies (Details) [Line Items]
Lease rental expense	$ 4,632
Headquarters Lease [Member]
Commitments and Contingencies (Details) [Line Items]
Rent paid				$ 7,076
WARF License Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Royalty fee					37,500	37,500	112,500	$ 100,000
Mayo Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Royalty fee					$ 5,727	$ 962	$ 6,417	$ 2,798

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of Supplemental Cash Flow Information Related to the Operating Lease - USD ($)	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash paid for amounts included in the measurement of lease liability:
Operating cash flows from operating leases	$ 100,562	$ 97,799
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$ 97,536

Commitments and Contingencies_4

Commitments and Contingencies (Details) - Schedule of Supplemental Balance Sheet Information Related to the Operating Lease - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Schedule of Supplemental Balance Sheet Information Related to the Operating Lease [Abstract]
Right-of-use assets	$ 197,324	$ 181,355
Lease liabilities	$ 214,482	$ 202,895
Weighted average remaining lease term (years)	1 year 8 months 12 days	2 years 4 months 24 days
Weighted average discount rate	7.80%	6.90%

Commitments and Contingencies_5

Commitments and Contingencies (Details) - Schedule of Maturity of the Lease Liabilities	Jun. 30, 2023 USD ($)
Schedule of Maturity of the Lease Liability [Abstract]
2023	$ 68,139
2024	139,969
2025	21,227
Total lease payments	229,335
Less imputed interest	(14,853)
Total	214,482
Short-term portion in accrued expenses and other liabilities	(125,564)
Long-term portion	$ 88,918

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Supplemental Balance Sheet Information [Abstract]
Deferred issuance costs	$ 67,159		$ 67,159
Amortization expense	5,578	$ 5,578	16,736	$ 16,736
Depreciation expense	$ 51,380	$ 25,928	$ 120,021	$ 68,462

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information (Details) - Schedule of Prepaid and Other Assets - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Schedule of Prepaid and Other Assets [Abstract]
Prepaid expenses	$ 211,627	$ 296,649
Deferred offering costs	67,159
Total	$ 278,786	$ 296,649

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information (Details) - Schedule of Inventory Consisted - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Schedule of Inventory Consisted [Abstract]
Work-in-process	$ 1,323,508	$ 630,570
Finished goods	193,019	73,968
Total	$ 1,516,527	$ 704,538

Supplemental Balance Sheet In_6

Supplemental Balance Sheet Information (Details) - Schedule of Intangible Assets	9 Months Ended
	Jun. 30, 2023 USD ($)
Supplemental Balance Sheet Information (Details) - Schedule of Intangible Assets [Line Items]
Net Intangibles, beginning	$ 111,892
Less: amortization	(16,736)
Net Intangibles, ending	$ 95,156
Minimum [Member]
Supplemental Balance Sheet Information (Details) - Schedule of Intangible Assets [Line Items]
Net Intangibles, beginning	12 years
Maximum [Member]
Supplemental Balance Sheet Information (Details) - Schedule of Intangible Assets [Line Items]
Net Intangibles, beginning	13 years

Supplemental Balance Sheet In_7

Supplemental Balance Sheet Information (Details) - Schedule of Property and Equipment - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Schedule of Property and Equipment [Abstract]
Equipment and furniture	$ 891,356	$ 538,061
Software		1,895
Total property and equipment	891,356	539,956
Less accumulated depreciation	(304,483)	(186,357)
Property and equipment, net	$ 586,873	$ 353,599

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - Schedule of Accrued Expenses - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Accrued Expenses and Other Liabilities [Abstract]
Accrued payroll	$ 582,806	$ 521,368
Operating lease liability, short term	125,564	83,339
Royalty payments	80,727	111,132
Total	$ 789,097	$ 715,839

Zimmer Development Agreement (D

Zimmer Development Agreement (Details) - USD ($)		3 Months Ended		9 Months Ended
	Aug. 02, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Zimmer Development Agreement (Details) [Line Items]
Initial fee payment				$ 2,000,000
Milestone payments paid	$ 3,500,000
Warrant exercise price (in Dollars per share)				$ 3
Risk-free interest rate				2.90%
Expected volatility percentage				53.50%
Expected life				5 years
Expected dividend yield percentage		0%	0%	0%	0%
Aggregate transaction price				$ 5,400,000
Initial exclusivity fee				2,000,000
Payments				3,500,000
Fair value of warrants				100,000
Recognized revenue		$ 0	$ 0	1,455,188	$ 6,374
Product revenue		629,906	32,049	1,210,661	102,381
Total advertising expense		$ 49,492	$ 43,479	156,131	$ 218,011
Development Agreement [Member]
Zimmer Development Agreement (Details) [Line Items]
Milestone payments paid	2,000,000
Payment fee	$ 1,500,000
Fair value of warrant				$ 100,000
Common Stock [Member]
Zimmer Development Agreement (Details) [Line Items]
Aggregate shares (in Shares)				350,000

Zimmer Development Agreement _2

Zimmer Development Agreement (Details) - Schedule of Deferred Revenue - USD ($)	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Deferred Revenue
Balance as of beginning of period	$ 1,455,188	$ 8,622
Revenue recognized	(1,455,188)	(6,374)
Balance as of end of period		$ 2,248

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)			3 Months Ended		9 Months Ended
	Jan. 01, 2023	Oct. 04, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2022
Stock-Based Compensation (Details) [Line Items]
Granted shares			339,000	88,890	469,512	150,690
Weighted-average grant date fair value, per share (in Dollars per share)					$ 0.88	$ 0.76
Total expense (in Dollars)					$ 482,276	$ 444,891
Total number of stock options outstanding			1,708,906		1,708,906		1,239,915
Restricted stock units vested					282,172	265,901
Stock options forfeited					521	27,668
Aggregate shares			249,000	87,720	310,728	443,670
Vesting percentage					50%
Total expense (in Dollars)					$ 351,935	$ 246,445
Reserved share		420,350
Shares outstanding percentage					13%
Option plan shares	129,479
Future issuance shares			1,129,125		1,129,125
Unrecognized share based compensation (in Dollars)					$ 1,745,365
Weighted average period					2 years
Stock Options [Member]
Stock-Based Compensation (Details) [Line Items]
Fair value grants issued (in Dollars per share)			$ 0.92	$ 0.57
Total expense (in Dollars)			$ 158,528	$ 137,109
Board of Directors [Member]
Stock-Based Compensation (Details) [Line Items]
Restricted stock units vested			69,947	64,841
Stock options forfeited			521	5,167
Restricted Stock [Member]
Stock-Based Compensation (Details) [Line Items]
Fair value grants issued (in Dollars per share)			$ 1.59	$ 1.14	$ 1.6	$ 1.91
Restricted stock units vested			52,299	9,606	294,109	18,694
Total expense (in Dollars)			$ 137,874	$ 118,439

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of Stock-Based Compensation Expense - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Schedule of Stock Based Compensation Expense [Abstract]
Selling, general and administrative	$ 237,007	$ 211,472	$ 691,939	$ 569,347
Research and development	59,395	44,076	142,272	121,989
Total stock-based compensation expense	$ 296,402	$ 255,548	$ 834,211	$ 691,336

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions Used in the Black-Scholes Option-Pricing Model	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Schedule of Weighted Average Assumptions Used in The Black Scholes Option Pricing Model [Abstract]
Expected stock price volatility	58.10%	53.50%	57.40%	53.50%
Expected life of options (years)	6 years 1 month 6 days	5 years 3 months 18 days	5 years 9 months 18 days	5 years 7 months 6 days
Expected dividend yield	0%	0%	0%	0%
Risk free interest rate	3.60%	2.80%	3.70%	2.30%

Concentrations (Details)

Concentrations (Details)	9 Months Ended
	Jun. 30, 2023
Concentrations [Abstract]
Number of customer	One

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Taxes [Abstract]
Effective tax rate	0%	0%	0%	0%
Income tax benefit

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Dec. 21, 2022	Jun. 30, 2023	Jun. 30, 2023	Nov. 15, 2021	Oct. 13, 2021
Stockholders' Equity (Details) [Line Items]
Aggregate offering price (in Dollars)	$ 14,500,000
Fixed commission rate	3%
Shares of common stock		1,439,677	1,439,677	422,057
Gross proceeds (in Dollars)			$ 2,552,656
Issuance costs (in Dollars)			$ 234,725
Issuance of shares					3,750,000
Additional shares purchased			562,500
Warrants Expired		425,370	695,848
Public Offering [Member]
Stockholders' Equity (Details) [Line Items]
Offering price, per share (in Dollars per share)					$ 3.2
Gross proceeds (in Dollars)			$ 13,400,000
Other offering issuance costs (in Dollars)			$ 1,400,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of Summarizes Information About Warrants Outstanding - Warrant [Member]	9 Months Ended
	Jun. 30, 2023 $ / shares shares
Class of Warrant or Right [Line Items]
Number Outstanding, Total	6,407,495
Number Exercisable , Total	6,407,495
3.00 [Member]
Class of Warrant or Right [Line Items]
Exercise Price, Total (in Dollars per share) | $ / shares	$ 3
Number Outstanding, Total	350,000
Weighted Average Remaining Contractual life (Years), Total	4 years 1 month 2 days
Number Exercisable , Total	350,000
5.25 [Member]
Class of Warrant or Right [Line Items]
Exercise Price, Total (in Dollars per share) | $ / shares	$ 5.25
Number Outstanding, Total	4,166,682
Weighted Average Remaining Contractual life (Years), Total	2 years 6 months 18 days
Number Exercisable , Total	4,166,682
5.61 [Member]
Class of Warrant or Right [Line Items]
Exercise Price, Total (in Dollars per share) | $ / shares	$ 5.61
Number Outstanding, Total	220,855
Weighted Average Remaining Contractual life (Years), Total	5 years 3 days
Number Exercisable , Total	220,855
6.00 [Member]
Class of Warrant or Right [Line Items]
Exercise Price, Total (in Dollars per share) | $ / shares	$ 6
Number Outstanding, Total	45,171
Weighted Average Remaining Contractual life (Years), Total	1 year 3 days
Number Exercisable , Total	45,171
7.50 [Member]
Class of Warrant or Right [Line Items]
Exercise Price, Total (in Dollars per share) | $ / shares	$ 7.5
Number Outstanding, Total	279,727
Weighted Average Remaining Contractual life (Years), Total	8 months 1 day
Number Exercisable , Total	279,727
8.25 [Member]
Class of Warrant or Right [Line Items]
Exercise Price, Total (in Dollars per share) | $ / shares	$ 8.25
Number Outstanding, Total	62,906
Weighted Average Remaining Contractual life (Years), Total	1 year 3 days
Number Exercisable , Total	62,906
9.00 [Member]
Class of Warrant or Right [Line Items]
Exercise Price, Total (in Dollars per share) | $ / shares	$ 9
Number Outstanding, Total	1,282,154
Weighted Average Remaining Contractual life (Years), Total	5 months 4 days
Number Exercisable , Total	1,282,154

Deferred Contribution Plan (Det

Deferred Contribution Plan (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Deferred Contribution Plan [Abstract]
Employees compensation percentage			100%
Deferrals percentage			100%
Contributions percentage			3%
Internal revenue percentage			100%
Contributions amount	$ 0	$ 0	$ 30,697	$ 30,697

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)		9 Months Ended
	Jul. 24, 2023	Jun. 30, 2023	Jul. 27, 2023
Subsequent Events (Details) [Line Items]
Common stock, shares issued		1,439,677
Gross proceeds		$ 2,552,656
Issuance costs		$ 234,725
Aggregate amount	$ 2,560,000
Issuance shares	5,250,000
Common stock par share	$ 0.001
Price per share	$ 1
Additional shares	787,500
Net proceeds	$ 5,214,875
Common Stock [Member]
Subsequent Events (Details) [Line Items]
Aggregate shares			6,037,500